Pinion Immunotherapeutics CEO Dr. Gregory Glenn to Speak at World Vaccine Congress Europe 2026 in Amsterdam

Skip to Content News Archives Economy Defence Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Defence Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Defence Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Pinion Immunotherapeutics CEO Dr. Gregory Glenn to Speak at World Vaccine Congress Europe 2026 in AmsterdamAuthor of the article:Panel on chronic conditions and off-target effects of vaccines, and a presentation on Pinion’s EBV immunotherapeutic programTHIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountROCKVILLE, Md. — Pinion Immunotherapeutics, a clinical-stage biotechnology company developing AI-designed mRNA immunotherapeutics for latent viral infections and virus-driven cancers, today announced that Chief Executive Officer Dr. Gregory Glenn will take part in two sessions at the 27th World Vaccine Congress Europe, held October 19 to 21 at the RAI Convention Centre in Amsterdam.This advertisement has not loaded yet, but your article continues below.Panel: Monday, October 19Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againCancer & Therapeutic Vaccines Workshop panel, “Chronic Conditions and Off-Target Effects of Vaccines”Monday, October 19, 2026, 12:15 to 13:00 CEST (6:15 to 7:00 am ET)Atrium 2, RAI Convention Centre, Europaplein 24, AmsterdamModerator: Robbert van der Most, Chief Executive Officer, VaxxcellenceAsimenia Angelidou, Assistant Professor of Paediatrics, Harvard Medical SchoolNicholas Perombelon, Head of Vaccines and Therapies for Infectious Diseases Office, European Medicines AgencyGregory Glenn, Chief Executive Officer, Pinion ImmunotherapeuticsKatharina Mühlhoff, Assistant Professor of Medicine, Heidelberg Institute of Global HealthPresentation: Wednesday, October 21Presentation, “Pinion’s AI-Designed mRNA Platform for Establishing Immune Control of EBV, from Mono to MS to Malignancy”Wednesday, October 21, 2026, 14:15 to 14:30 CEST (8:15 to 8:30 am ET)Track 1 (Infectious Diseases), RAI Convention Centre, AmsterdamGregory Glenn, Chief Executive Officer, Pinion ImmunotherapeuticsEpstein Barr virus was the first virus shown to cause human cancer, and it infects most adults worldwide for life. There are no FDA approved EBV vaccines or treatments after 60 years of research. The connection between latent viral infection and chronic disease is a hot area of biology, and it is drawing growing attention from researchers, regulators and industry. Dr. Glenn will discuss how Pinion is designing mRNA immunotherapeutics intended to help adults restore immune control to prevent and cure disease stemming from EBV infections, building on the company’s HPV program, ARV-2001, which has an FDA cleared IND.Dr. Glenn previously served as President of Research and Development at Novavax, where he led development of the Nuvaxovid COVID-19 vaccine.About Pinion ImmunotherapeuticsPinion Immunotherapeutics (ARV Technologies, Inc.) is a clinical-stage biotechnology company based in Maryland developing AI-designed mRNA immunotherapeutics for latent viral infections and virus-driven cancers. Its lead program, ARV-2001, targets HPV-16 cervical precancer as a potential non-surgical alternative to LEEP. The pipeline also includes programs in EBV, HSV, AML and KRAS-driven solid tumors, and a partnered HBV program. Learn more at pinionimt.com.View source version on businesswire.com: Sia Anagnostou, Chief Business Officer, Pinion Immunotherapeutics Dr. Glenn is available for interviews in Amsterdam October 19 to 21.This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.